Curetis to Present at Key Investor and Scientific Conferences in the Fourth Quarter 2017


06.10.17 09:05
Meldung
 
Curetis to Present at Key Investor and Scientific Conferences in the Fourth Quarter 2017

Curetis /Curetis to Present at Key Investor and Scientific Conferences in the Fourth Quarter 2017 . Processed and transmitted by Nasdaq Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Curetis to Present at Key Investor and Scientific Conferences in the Fourth Quarter 2017

Amsterdam, the Netherlands, and Holzgerlingen, Germany, October 6, 2017 -- published at 08:00 am CET -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced its participation in several industry conferences in the fourth quarter of 2017. The respective presentations will be made available on the company's website.

October

Large and Midcap Conference 2017, October 4-5, 2017 - Paris, France: One-on-one meetings.

ID Week 2017, October 4-8, 2017 - San Diego, CA, USA: Booth 637.

CRIOAC 2017 CRIOAC, October 19-20, 2017 - Tours, France.

DKOU 2017, October 23-27, 2017 - Berlin, Germany: Hall 2.2b, booth 68.

November

Biotech & Money Inv€$tival Showcase Event, November 14, 2017 - London, UK: One-on-one meetings and presentation.

Jefferies Global Healthcare Conference 2017, November 15-16, 2017 - London, UK: One-on-one meetings.

AMP 2017, November 16-19, 2017 - Salt Lake City, UT, USA: Booth 1801.

###

About Curetis

Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.

In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximize the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.

For further information, please visit www.curetis.com.

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contact details

Curetis

Max-Eyth-Str. 42

71088 Holzgerlingen, Germany

Tel. +49 7031 49195-10

pr@curetis.com or ir@curetis.com

www.curetis.com - www.unyvero.com

International Media & Investor Inquiries

akampion

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

info(@)akampion.com

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68

U.S. Media & Investor Inquiries

The Ruth Group

Lee Roth

lroth@theruthgroup.com

Tel. +1 646 536 7012

Curetis_Logo

20171006_Curetis_PR_EN_Q4 Conferences






This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Curetis via Globenewswire


--- End of Message ---



Curetis

Max-Eyth-Str. 42 Holzgerlingen Germany





Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;





 

Breaking News


Kurs- und weitere Informationen zum Thema:

Curetis N.V.

Aktuelle Diskussionen zum Thema:

CURETIS N.V. AAN T. Chancen ... (27.04.17)

Aktuelle Nachrichten zum Unternehmen:


Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Curetis N.V.
Weitere Meldungen
 
06.10 Ad hoc: Holmes Investment .
06.10 Ageas and Norges Bank: Tr.
06.10 Ad hoc: Klarstellung: Überna.
06.10 Klövern AB (publ): Klövern .
06.10 Karo Pharma AB completes.
06.10 Ad hoc: RWE Aktiengesells.
06.10 Curetis kündigt Teilnahme an.
06.10 Curetis to Present at Key I.
06.10 Metso appoints three Busine.
06.10 Vaisala's Interim Report Jan.
06.10 Scatec Solar closes financin.
06.10 Wentworth Resources Limite.
05.10 MPLX LP to announce 2017.
05.10 Marathon Petroleum Corp. to.
05.10 Ad hoc: OHB SE: Europäisc.
05.10 EQS-Adhoc: Kapitalerhöhung.
05.10 Ad hoc: OTI Greentech AG.
05.10 Sanofi : Appellate Court Ord.
05.10 Ad hoc: Pfeiffer Vacuum T.
05.10 Final result of the voluntary.
05.10 SpareBank 1 SMN : Possible.
05.10 Ad hoc: WASGAU Produkt.
05.10 Ad hoc: GBS Software AG.
05.10 Wolters Kluwer N.V.: Share.
05.10 Ad hoc: M1 Kliniken AG sc.
05.10 Ad hoc: Dialog Semiconduct.
05.10 Cegereal, the French Core O.
05.10 Telenor and Cisco introduce .
05.10 Songa Offshore SE : Septe.
05.10 TiGenix to present positive .


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 34825 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Barrick Gold: Das war knapp!
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
Devin Sage TXA Trading ...
Devin Sage, Technische-X-Analyse.de (21:14)
Experte: Devin Sage, Technische-X-Analyse.de
Bitcoin/ Ethereum - Jetzt ...
Philip Hopf, Hopf Klinkmüller Capital. (18:28)
Experte: Philip Hopf, Hopf Klinkmüller Capital Management K.
DOW DAX mit dem Sturm
Thomas Heydrich, Systemstradings.de (17:27)
Experte: Thomas Heydrich, Systemstradings.de
DAX rutscht ab – Harter ...
CMC Markets, (17:25)
Experte: CMC Markets,
RWE, Deutsche Bank, ...
Feingold-Research, (17:17)
Experte: Feingold-Research,
S&P500 bei 2.630 Punkten
Christian Zoller, www.boerse-daily.de (16:10)
Experte: Christian Zoller, www.boerse-daily.de
Bitcoin in Gold tauschen
Benjamin Summa, pro aurum (16:03)
Experte: Benjamin Summa, pro aurum
Dax – da braut sich was ...
Cornelia Frey, Börse Stuttgart AG (15:55)
Experte: Cornelia Frey, Börse Stuttgart AG
Macron will die Europäische ...
Claus Vogt, (15:22)
Experte: Claus Vogt,
Clariant-Aktien tauchen ...
Robert Sasse, (14:59)
Experte: Robert Sasse,
Goldpreis unter Druck
Björn Junker, GOLDINVEST.de (14:28)
Experte: Björn Junker, GOLDINVEST.de
EUR/USD Analyse: Neue ...
Admiral Markets, (13:52)
Experte: Admiral Markets,
Niquet's World
Neues vom Portal
 
Wie uns das Internet das Vergleichen so einfach wie nie zuvor macht
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen